Adams Clinical
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Adams Clinical - overview
Established
2011
Location
Watertown, MA, US
Primary Industry
Healthcare
About
Based in Massachusetts, US, and founded in 2011, Adams Clinical operates as a medical research company that is engaged in the ate-phase clinical trials for psychiatric and neurological drugs. In May 2024, InTandem Capital Partners acquired Adams Clinical through recapitalization. As of May 2024, the company is being led by its CEO, Nelson Rutrick. The firm operates clinical trial site networks with locations across the Northeast that conduct independent investigational drugs in double-blind, randomized, placebo-controlled studies of drugs to treat psychiatric and neurologic illnesses.
The firm conducts clinical trials of various drugs like depression, mild Alzheimer’s, etc. on consulting humans.
Current Investors
InTandem Capital Partners
Primary Industry
Healthcare
Sub Industries
Healthcare
Website
www.adamsclinical.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Adams Clinical - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Recapitalisation | Completed | Adams Clinical | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.